New Artery-on-a-Chip Technologies Advance Construction Strategies and Disease Modeling

Cardiovascular disease remains the world’s leading cause of death, and the arteries—dynamic tubes that constantly bend, stretch, pulse and respond to flowing blood—are where many of its most dangerous forms begin. A new review argues that a technology small enough to fit on a microscope slide could help researchers study these diseases with a realism that conventional laboratory models often cannot provide. Known as the artery-on-a-chip, the platform combines microfluidics, tissue engineering and biomaterials to recreate sections of human arteries in controlled laboratory devices. The review, published in Angiogenesis, surveys how these systems are built and how they are being adapted to investigate thrombosis, atherosclerosis, pulmonary hypertension and aneurysms. Its central message is that the future of vascular research may depend on reproducing not only the cells lining an artery, but also the physical forces that shape their behaviour.

For decades, researchers have relied heavily on animal models and two-dimensional cell cultures to investigate arterial disease and test potential medicines. Both approaches have provided essential biological insights, but each captures only part of the environment inside a living artery. Flat cultures usually grow cells on rigid plastic, eliminating the three-dimensional architecture of the vessel wall and exposing cells to an artificial mechanical setting. Animals, meanwhile, can reproduce complex physiology but differ from humans in anatomy, immune responses, metabolism and disease progression. These differences can make a treatment appear promising before clinical testing, only for its effects to be weaker—or absent—in people. Artery-on-a-chip systems are designed to occupy the space between these extremes by offering human cells in a structured, perfused and mechanically active microenvironment that can be observed and manipulated in real time.

At its simplest, an artery-on-a-chip contains a microscopic channel through which a liquid is pumped, mimicking blood flow, alongside or within a compartment containing vascular cells and a supporting matrix. More sophisticated devices reproduce the layered structure of an arterial wall. Endothelial cells form the inner lining, vascular smooth-muscle cells provide contractile support in the media, and additional stromal or connective-tissue components can help model the outer vessel environment. The channel may be circular rather than rectangular, allowing researchers to approximate the geometry of a natural artery. Flexible materials can permit the channel to expand and contract as pressure changes, while membranes or hydrogel layers can separate cell populations without preventing biochemical communication. Some designs use three-dimensional printing or bioprinting to create bends, branches, stenoses and patient-specific geometries that would be difficult to reproduce in ordinary culture dishes.

The review emphasizes that biological fidelity depends on a carefully balanced set of design parameters. The extracellular matrix, the network of proteins surrounding cells, provides both biochemical signals and mechanical resistance. Collagen, elastin-like materials, gelatin-based hydrogels and engineered biomaterials can be tuned to reproduce different levels of stiffness and elasticity. This matters because arterial cells sense their surroundings through mechanotransduction: molecular systems convert physical inputs into changes in gene expression, cytoskeletal organization and cell function. Endothelial cells also respond to wall shear stress, the frictional force produced by flowing fluid along the vessel surface. Under steady, directional flow, they tend to elongate and align with the direction of movement. Disturbed or oscillating flow can trigger inflammatory signalling, weaken barrier function and promote the cellular changes associated with atherosclerosis. A chip that controls flow therefore becomes a way to expose cells to specific mechanical conditions rather than merely keeping them alive.

Pressure and cyclic stretch add another layer of realism. Arteries do not experience a constant diameter: each heartbeat sends a pressure wave through the vessel, repeatedly deforming the wall. Researchers can reproduce this behaviour by applying pneumatic pressure, deforming flexible chambers or controlling the compliance of the surrounding material. Cyclic strain influences vascular smooth-muscle cells, which can shift between contractile, proliferative, synthetic and inflammatory states. These phenotypic changes are important in arterial stiffening, plaque development and aneurysm formation. Matrix stiffness is equally consequential. A rigid environment can alter the response of endothelial cells to shear stress and may interfere with normal mechanosensing. By independently adjusting stiffness, stretch, pressure and flow, artery-on-a-chip experiments can dissect how physical factors interact—something that is difficult to achieve in a living animal or a standard two-dimensional culture.

One of the most immediate applications is the study of arterial thrombosis, in which platelets and blood-clotting proteins accumulate to obstruct blood flow. A chip can incorporate narrowed regions, damaged or activated endothelium and controlled pulses of whole blood, allowing investigators to observe platelet adhesion, activation and aggregation under defined shear conditions. The geometry is critical: blood moving through a stenosis accelerates, separates and forms complex flow patterns downstream. These local changes can influence how von Willebrand factor unfolds, how platelets attach and how a fragile deposit develops into a more stable thrombus. Researchers can then introduce antiplatelet or anticoagulant drugs and measure how effectively they prevent or dissolve clot formation. Because the device can be imaged continuously, it may reveal the difference between a treatment that reduces platelet attachment and one that merely slows the later growth of an established clot. The review also highlights the growing use of three-dimensional printing and anatomically accurate geometries, including patient-specific arterial shapes, to make thrombosis models more clinically relevant.

Atherosclerosis presents a broader challenge because it develops through a long interaction among endothelial dysfunction, lipids, immune cells, smooth-muscle cells and the extracellular matrix. Artery-on-a-chip models can recreate some of these interactions under flow, including the disturbed haemodynamics found near branches, curves and narrowed segments. Researchers may perfuse blood or selected immune-cell populations through a channel lined with endothelial cells, then examine how monocytes attach, migrate into the vessel wall and contribute to inflammation. In multilayer systems, smooth-muscle cells can move beneath the endothelium, while fluorescent particles or lipoproteins are tracked as they cross the endothelial barrier. Single-cell analysis and high-resolution imaging can add molecular detail, identifying shifts in cell state that are hidden when all cells are averaged together. Such platforms could also help test therapies aimed at vascular inflammation, plaque stability or atherothrombosis, while reducing dependence on animal models whose plaque biology does not always match that of humans.

The technology is being extended beyond atherosclerosis and clotting. Pulmonary hypertension, a disease marked by abnormal remodelling and increased resistance in the pulmonary arteries, can be modelled by combining endothelial cells, smooth-muscle cells and disease-relevant mechanical conditions. The review describes how such systems may help investigate signalling pathways linked to endothelial dysfunction and smooth-muscle proliferation, including pathways involving BMPR2 and SOX17. Aneurysm models focus on the progressive weakening and expansion of the arterial wall. By tuning wall stiffness, cyclic stretch and cellular composition, researchers can study how smooth-muscle cells lose their contractile identity, how matrix-degrading processes reshape the vessel and how abnormal flow concentrates mechanical stress. Patient-derived cells and induced pluripotent stem-cell-derived vascular cells offer a route toward models that reflect individual genetic or disease characteristics. In principle, a patient-specific artery-on-a-chip could allow a medicine to be assessed against the biology of a particular person rather than an average laboratory vessel.

Despite the excitement, the review makes clear that artery-on-a-chip systems are not yet a universal replacement for animals or clinical studies. Long-term culture remains difficult: cells may lose their specialised identity, membranes can deteriorate, hydrogels can remodel and microfluidic channels can clog or absorb small drug molecules. Polydimethylsiloxane, a widely used chip material, is flexible and easy to manufacture, but its tendency to absorb hydrophobic compounds can distort pharmacological measurements. Devices also differ widely in channel dimensions, materials, cell sources, flow rates and reporting standards, making results difficult to compare across laboratories. Real arteries contain multiple interacting cell types, circulating blood components, nerves, immune signals and organ-level influences that a single chip may not capture. The researchers therefore call for greater standardization, improved long-term stability and models capable of coupling several disease factors at once. They envision future systems that integrate patient-derived cells, realistic anatomy, programmable haemodynamics, advanced imaging and automated analysis. If those challenges can be overcome, the artery-on-a-chip could become more than a miniature vessel: it could serve as a dynamic testing ground for discovering why arteries fail, predicting which treatments will work and bringing vascular therapies closer to the biology of real patients.